### **Overview** Vaidya Sane Ayurved Laboratories Limited operates under the brand name **Madhavbaug**, a pioneering integrated healthcare provider focused on the **non-invasive reversal of chronic lifestyle diseases** using **Ayurveda combined with modern diagnostics and technology**. Founded in 1999 and headquartered in **Pune, Maharashtra**, with a corporate office in Thane, the company has evolved into one of India’s most scientifically validated Ayurvedic healthcare networks. Madhavbaug specializes in treating **heart disease, diabetes, hypertension, obesity, and joint pain**, with a mission to reduce mortality and morbidity from non-communicable diseases (NCDs). It uniquely blends **Panchakarma therapies, diet protocols, herbal medicines**, and **lifestyle modification** with modern diagnostic tools such as **2D Echo, CT angiography, stress tests**, and continuous health monitoring. --- ### **Core Business Model: Dual-Channel, Asset-Light Scalability** #### **1. Clinic Network (Primary Revenue Driver)** - **Scalable Franchise Model**: 86% of enterprise revenue is generated through clinic operations, predominantly via a **capital-light franchise model**. - **Network Size**: - As of **September 30, 2025**, Madhavbaug operated **~320 clinics** across 8 states: 22 company-owned, 45 OPD/mini clinics, and 255 franchise clinics. - Earlier estimates (Sep 2024–Mar 2025) place the network at **333 to 353 clinics** across up to 18 states, indicating consolidation or reclassification. - **Expansion Plans**: - Add **40–50 clinics in FY26**, and **70–80 more in FY27**, focusing on **Tier 2 and Tier 3 cities**. - Target: **1,000 clinics by 2030**, with a strong rural India focus. #### **2. Hospitals & Cardiac Rehabilitation** - **Currently Operates**: - **4 specialized cardiac prevention and rehabilitation hospitals** in **Khopoli (Maharashtra), Nagpur (Maharashtra), Vadodara (Gujarat), and Visakhapatnam (Andhra Pradesh)**. - Total bed capacity: **110–120 beds** (expanded from prior 100-bed estimate after new Vadodara launch). - **NABH Accreditation**: - Flagship **Khopoli hospital is NABH-accredited**, as are **Nagpur (Kondhali)** and potentially others — positioning Madhavbaug as **one of the few NABH-accredited Ayurvedic institutions** in India. - **Expansion**: - Plans to scale total hospital beds to **250–300 within 12–15 months**. - **Target 1,000 beds nationwide within 2–3 years**. - Capital expenditure of **~INR 25 crores** allocated for expansion at Khopoli and Nagpur, using **owned, rental, and PPP models**. --- ### **Clinical Efficacy & Patient Outcomes** - **80–85% patient retention rate** in franchise clinics. - **65% documented disease reversal rate** across core conditions. - **Monthly new patient inflow**: 9,000–10,000 (May 2025), aiming for **12,000–13,000/month by FY26**. - **Annual new patient targets**: - **82,000 in FY25** - **120,000–130,000 in FY26** - **200,000 by FY28** --- ### **Revenue & Financial Highlights (FY25)** - **Revenue**: ₹89.85 crore in FY25 (down from ₹99.33 crore in FY24), reflecting strategic restructuring and cost focus. - **EBITDA**: **₹13.5 crore** (near **200% YoY increase**). - **PAT**: **₹7.15 crore** (**259% YoY growth**), driven by **operational efficiency and cost optimization**. - **Revenue Forecast**: **INR 115–120 crores for FY26**. - **Revenue from Insurance/TPA**: **~14% of total revenue**, with plans to grow this significantly. --- ### **Key Strategic Initiatives & Growth Drivers** #### **1. Insurance & Government Empanelment** - Empaneled with **over 30 insurance companies via 15+ TPAs**, including **Star Health**. - **Cashless treatments** available at **Khopoli and Nagpur hospitals**, with **Vadodara and Visakhapatnam hospitals under development**. - Active pursuit of **CGHS and GIPSA empanelment** to access government employee populations — **Nagpur and Vadodara hospitals nearing approval**. - Up to **30% of Khopoli hospital occupancy** from insurance-based admissions. #### **2. Digital & Technological Integration** - **MIB Pulse App**: A chat-based digital platform serving **2.5+ lakh patients**, enabling remote consultations, follow-ups, and care continuity. - **Madhavbaug POWER MAP**: Proprietary diagnostic tool for **in-depth medical analysis** using AI and clinical data. - **AI Chatbot**: Launched to improve patient engagement. - **Mobile Medical Units (MMUs)** and **telemedicine** to improve accessibility. #### **3. Product Division & In-House Manufacturing** - **Fully integrated value chain** via subsidiaries: - **Dynamic Remedies Pvt. Ltd. (100% subsidiary)**: Primary manufacturer of Ayurvedic medicines. - **UV Ayurgen Pharma Pvt. Ltd. (100% subsidiary)**: Produces nutraceuticals and health foods using **green technology**. - Key branded products: - *Madhavprash* (herbal immunity and heart health product) - *Prameha Gummies* and *Prameha* (for diabetes) - *Hrudyam Tea*, *Fungarest*, *Madhavshakti Atta*, and *Prameha Diet Kit* - Products available on **Amazon, 1MG**, and company's **e-commerce platform**. - Developing **ready-to-cook and ready-to-eat formats** for broader retail scalability. #### **4. Brand, Marketing & Patient Acquisition** - Appointed **Sonu Sood as Brand Ambassador** (April 2025), shifting from digital-only to **ground-level outreach**, boosting awareness and credibility. - **ATL + BTL Marketing Mix**: Radio, TV, print, digital, events. - Focus on **corporate wellness programs**: Delivered services to **80,000+ police personnel** and **80,000 Konkan Railway employees**. - Partnerships with **Reliance, JSW, SBI Pensioners**, and others. --- ### **Innovation & Expansion Beyond Clinical Care** #### **1. Swasthya Parivaar Community Platform** - **Paid membership model** focused on **Diagnose → Manage → Cure** framework. - Targets **1 lakh members in FY25**, scaling to **10 lakh in 5 years**. - Goals: - Reduce customer acquisition cost via **peer referrals and word-of-mouth** - Provide **affordable, continuous care** for lifestyle diseases - Increase regular footfall to clinics and hospitals #### **2. Madhavbaug Associate Program** - **Education and affiliation model** for **BAMS doctors** to practice under Madhavbaug, sell products, and access protocols. - Target: Onboard **1,000+ associates** to expand medical network. #### **3. Subsidiaries & Strategic Investments** | Entity | Stake | Function | |-------|--------|---------| | **Dynamic Remedies Pvt. Ltd.** | 100% | Manufacturing of Ayurvedic medicines | | **UV Ayurgen Pharma Pvt. Ltd.** | 100% | Nutraceuticals, food products | | **F-Health Accelerators Pvt. Ltd.** | 80% | Startup incubator (D2C, telemedicine, Med-tech) – invested in *SNA Milk*, *Justkare* | | **Cure & Care (Raphacure)** | 17.5% | Telemedicine, diagnostics | | **Easy Ayurveda Pvt. Ltd.** | 15% | Global Ayurveda education with Dr. Janardhan Hebbar | | **Aaharshashtra Foodz Pvt. Ltd.** | 20% | Healthy food recipes, workshops | | **Joint Healing Services Pvt. Ltd.** | 0.5% | Holistic pain management programs | --- ### **International Expansion** - **First Global Venture**: Signed **MoU with Maxura Healthcare (Malaysia)** to establish **Maxura Ayurveda Healthcare** — a joint Ayurvedic therapy center. - Profit sharing: **70:30 in favor of Maxura** - Part of long-term global footprint strategy. - **Dubai Subsidiary**: Launched **Madhavbaug Health Food Supplements Trading Co. LLC** in Dubai for international product distribution. - **Future Goals**: Participate in global Ayurveda events (e.g., "Ayurveda Beyond Wellness" in USA), expand via medical value travel. --- ### **Research & Scientific Validation** - **150+ research papers** published in journals like *The Lancet* and *Indian Heart Journal*. - **Ongoing RCT with CCRAS** on Ayurvedic interventions for **Stable Coronary Artery Disease** using advanced imaging. - Research underway on **Ayurvedic treatments for kidney disease and congestive heart failure**. - **Study on CHF patients** accepted in *Asian Journal of Cardiology Research*: Shows **improved exercise capacity and reduced mortality risk** with Panchakarma.